CN111773258A - Mongolian medicine and pharmaceutical composition for resisting influenza virus, and preparation method and application thereof - Google Patents

Mongolian medicine and pharmaceutical composition for resisting influenza virus, and preparation method and application thereof Download PDF

Info

Publication number
CN111773258A
CN111773258A CN202010803851.5A CN202010803851A CN111773258A CN 111773258 A CN111773258 A CN 111773258A CN 202010803851 A CN202010803851 A CN 202010803851A CN 111773258 A CN111773258 A CN 111773258A
Authority
CN
China
Prior art keywords
pharmaceutical composition
influenza virus
influenza
parts
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010803851.5A
Other languages
Chinese (zh)
Other versions
CN111773258B (en
Inventor
包书茵
奥·乌力吉
王秀兰
包晓华
苏都那布其
苏维恒
王秀枝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202010803851.5A priority Critical patent/CN111773258B/en
Publication of CN111773258A publication Critical patent/CN111773258A/en
Application granted granted Critical
Publication of CN111773258B publication Critical patent/CN111773258B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a Mongolian medicine for resisting influenza virus, a pharmaceutical composition, a preparation method and an application thereof, and provides an application of belvedere fruit and/or a belvedere fruit water extract and/or a belvedere fruit alcohol extract in preparation of the pharmaceutical composition or the pharmaceutical preparation for resisting influenza virus, and provides a pharmaceutical composition prepared from the following raw materials in parts by weight: 45-55 parts of sargentgloryvine root, 25-35 parts of inula flower and 15-25 parts of fructus kochiae. The pharmaceutical composition disclosed by the invention has excellent anti-H1N 1 and/or anti-H3N 2 influenza virus effect and no toxic or side effect.

Description

Mongolian medicine and pharmaceutical composition for resisting influenza virus, and preparation method and application thereof
Technical Field
The disclosure relates to a Mongolian medicine for resisting influenza virus, a pharmaceutical composition, a preparation method and application thereof.
Background
The information in this background section is only for enhancement of some understanding of the general background of the disclosure and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art already known to a person of ordinary skill in the art.
Influenza viruses are called influenza viruses for short and are divided into three types, namely A (A), B (B) and C (C). The influenza virus can cause infection and morbidity of various animals such as human, poultry, pigs, horses, bats and the like, and is a pathogen of epidemic diseases of human and animals such as human influenza, avian influenza, swine influenza, horse influenza and the like. Human influenza is mainly caused by influenza a and influenza b viruses. Influenza a viruses often have antigenic variation and can be further divided into subtypes H1N1, H3N2, H5N1, H7N9 and the like (wherein H and N represent two surface glycoproteins of influenza viruses, respectively).
For influenza patients, western medicines such as interferon, amantadine and oseltamivir are mostly used for treatment, but the western medicines have great side effects and are easy to generate drug resistance. Aiming at the problem, the inventor performs previous research to obtain the inula flower which has obvious curative effect on influenza and does not generate drug resistance.
Disclosure of Invention
In view of the above background, the present inventors have conducted intensive studies on inula flowers, and found that inula flowers alone have an excellent effect against influenza viruses such as H1N1, but have a weak resistance against H3N 2. In view of the problem, the present disclosure provides an anti-influenza virus Mongolian medicine, a pharmaceutical composition and a preparation method and application thereof, wherein the anti-influenza virus Mongolian medicine is compatible with Salicornia bigelovii and Inulae flos, and the obtained pharmaceutical composition has excellent anti-H1N 1 effect and excellent anti-H3N 2 effect.
Specifically, the following technical scheme is adopted in the disclosure:
in a first aspect of the present disclosure there is provided the use of Kochiae fructus and/or aqueous and/or alcoholic extracts of Kochiae fructus in the manufacture of a pharmaceutical composition or formulation against influenza virus.
In a second aspect of the present disclosure, there is provided the use of kochia scoparia and/or a water extract of kochia scoparia and/or a kochia alcohol extract for the preparation of a pharmaceutical composition or pharmaceutical preparation capable of inhibiting the cytopathic effects caused by influenza virus infection and replication of viral genomic RNA in influenza virus infected cells.
In the present disclosure, the Kochia scoparia (L.) schrad, a plant of chenopodiaceae, and the aerial part of the Kochia scoparia and the fruit of the Kochia scoparia have an anti-influenza virus effect in the present disclosure.
The invention relates to a preparation method of a traditional Chinese medicine for treating skin itch, and the traditional Chinese medicine is mainly prepared from fructus kochiae, and the inventor surprisingly finds that the fructus kochiae and/or the water extract and/or the alcohol extract of the fructus kochiae have excellent anti-influenza virus effects, especially can effectively inhibit cytopathic effect caused by influenza virus infection and can effectively inhibit the replication of virus genome RNA in cells infected by the influenza virus.
In one or some embodiments of the present disclosure, the influenza virus is an influenza a virus and/or an influenza b virus, and the influenza a virus is an influenza a H1N1 virus and/or an influenza a H3N2 virus.
In one or some embodiments of the present disclosure, the aqueous extract of kochia scoparia is prepared by the following method:
decocting aerial parts of Kochiae fructus in water, and filtering; decocting the residue with water, and mixing filtrates to obtain fructus Kochiae water extract.
In one or some embodiments of the present disclosure, the alcohol extract of kochia scoparia is an alcohol extract of kochia scoparia.
Further, the fructus kochiae ethanol extract is prepared by the following method:
decocting aerial parts of Kochiae fructus with ethanol solution, and filtering; decocting the residue with ethanol solution, and mixing filtrates to obtain Kochiae fructus ethanol extract.
Furthermore, the volume fraction of the ethanol solution is 90-95%, and the active ingredients for resisting the influenza virus can be effectively extracted.
In a third aspect of the present disclosure, there is provided a pharmaceutical composition against influenza virus, comprising kochia scoparia or an active ingredient of kochia scoparia.
In one or more embodiments of the present disclosure, the effective component of kochia scoparia is prepared by water extraction or alcohol extraction.
In one or some embodiments of the present disclosure, the pharmaceutical composition is prepared from the following raw materials in parts by weight:
45-55 parts of sargentgloryvine root, 25-35 parts of inula flower and 15-25 parts of fructus kochiae.
Further, the pharmaceutical composition is prepared from the following raw materials in parts by weight:
50 parts of sargentgloryvine root, 30 parts of inula flower and 20 parts of broom cypress fruit.
Furthermore, the overground part and seeds of the agriophyllum squarrosum, the flowers of the inula flower and the fruits of the broom cypress fruit are used as medicines, and tests prove that the effect of resisting influenza viruses is more excellent when the overground part and the seeds of the agriophyllum squarrosum, the flowers of the inula flower and the fruits of the broom cypress fruit are used as medicines.
In the present disclosure, the Agriophyllum squarrosum is a mongolian drug named Chu-Zhi-Shi (Mongolian medicine-Zhengdian), and is named as Agriophyllum squarrosum (L.) Moq. The related records indicate that: treating pestilence, headache, red eye, jaundice, kidney heat, causalgia of urethra, thirst, aphtha, stomach-ache, and toxic heat.
In the present disclosure, the inula flower is a mongolian drug named alatan-dasule-the division thereof, known as inuibritanica l.var.japonica (Thubn.) franch.et sav, belonging to inula plants of the family compositae. The related records indicate that: it is used to treat "sticky" spur pain, "complication," fracture, and incised wound.
The pharmaceutical composition disclosed by the invention is constructed according to the traditional Mongolian medicine theory and the traditional Chinese medicine theory, comprises one traditional Chinese medicine and two Mongolian medicines, is an organic whole, is free from one component and can not be used, and the components have synergistic interaction, so that the technical problem of single H1N1 resistance can be effectively solved. Through experimental verification, the inventor finds that the overall effect of the pharmaceutical composition is remarkably reduced by reducing any pharmaceutical raw material or replacing the raw material components of the pharmaceutical composition with the bulk drugs with similar drug properties; the addition of other raw material components does not obviously improve the technical effect of the pharmaceutical composition, and the overall technical effect is reduced.
In a fourth aspect of the present disclosure, there is provided a preparation method of the pharmaceutical composition against influenza virus, the preparation method comprising the steps of:
mixing the raw materials in a certain weight ratio, and extracting with ethanol solution or water for several times to obtain extractive solution, i.e. the pharmaceutical composition.
In one or some embodiments of the present disclosure, the ethanol solution has a volume fraction of 90 to 95%, and is effective for extracting an active ingredient against influenza virus.
In a fifth aspect of the disclosure, a pharmaceutical preparation for resisting influenza virus is provided, which is prepared from the pharmaceutical composition and pharmaceutically acceptable excipients.
In one or some embodiments of the present disclosure, the pharmaceutical preparation may be prepared into various pharmaceutical dosage forms, such as decoction, pill, capsule, tablet, powder, granule, oral liquid, or the like.
In one or some embodiments of the present disclosure, pharmaceutically acceptable excipients in the pharmaceutical formulation include, but are not limited to: diluents include, but are not limited to, sorbitol, mannitol, starch, lactose, powdered or microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, sugars, and the like; filling agent: sodium carboxymethylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, gelatinized starch, and the like; disintegrating agent: dry starch, crospovidone, croscarmellose sodium, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, and the like; lubricant: magnesium stearate, sodium lauryl sulfate or aerosil; other adjuvants include one or more of binding agent, flowing agent, composite forming agent, plasticizer, colorant, sweetener, viscosity enhancer, preservative or antioxidant.
Compared with the related technology known by the inventor, one technical scheme of the disclosure has the following beneficial effects:
the pharmaceutical composition disclosed by the invention has excellent anti-H1N 1 and/or anti-H3N 2 influenza virus effect and no toxic or side effect, and has more excellent anti-H3N 2 influenza virus effect compared with a single medicinal material. Further, the subsequent verification of an influenza animal model shows that the pharmaceutical composition disclosed by the invention has an obvious relieving effect on influenza general symptoms, and the main symptoms comprise sweating, defervescence, pain relieving and the like.
Detailed Description
It should be noted that the following detailed description is exemplary and is intended to provide further explanation of the disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of example embodiments according to the present disclosure. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise, and it should be further understood that when the terms "comprises" and/or "comprising" are used in this specification, they specify the presence of the stated features, steps, operations and/or combinations thereof.
In order to make the technical solutions of the present disclosure more clearly understood by those skilled in the art, the technical solutions of the present disclosure will be described in detail below with reference to specific embodiments.
Example 1 preparation of extracts of fruits and aerial parts of Kochia scoparia
(1) Aqueous extracts
Taking 50g of dried mature fruits of belvedere fruit, adding 15 times of water, decocting for 40 minutes, filtering with 4 layers of gauze, adding 10 times of water on residues, decocting for 20 minutes, combining filtrates, and putting the combined filtrates on a water bath pot to be pasty to obtain 12g of pasty extract of the belvedere fruit.
Taking 50g of the overground part (without fruits) of the dried fructus kochiae, adding 16 times of water, decocting for 40 minutes, filtering 4 layers of gauze, adding 10 times of water into residues, decocting for 20 minutes, combining filtrates, and putting the mixed filtrates on a water bath pot to form paste to obtain 11g of the overground part water extract of the paste fructus kochiae.
(2) Ethanol extract
Taking 50g of dried and mature fruits of broom cypress fruit, adding 15 times of 95 v/v% ethanol solution, decocting for 30 minutes, filtering with 4 layers of gauze, adding 10 times of 95 v/v% ethanol solution on residues, decocting for 15 minutes, combining the filtrates, putting the mixture on a water bath pot to form paste, and 3.9g of ethanol extract of overground part of paste broom cypress fruit.
Taking 50g of the overground part of the dry fructus kochiae, adding 14 times of 95 v/v% ethanol solution, decocting for 30 minutes, filtering by 4 layers of gauze, adding 10 times of 95 v/v% ethanol solution on residues, decocting for 15 minutes, combining the filtrate, putting the mixture on a water bath pot until the mixture is pasty, and 3.7g of the ethanol extract of the overground part of the pasty fructus kochiae.
EXAMPLE 2 preparation of Compound extract
Mixing dried flos Inulae, dried fruit of Kochiae fructus, aerial part of herba Salicorniae Glabrae and seed at a mass ratio of 2:3:5, collecting 50g of mixed medicinal materials, pulverizing, adding 14 times of water, decocting for 30 min, filtering with 4 layers of gauze, adding 7 times of water to the residue, decocting for 15 min, and mixing filtrates to obtain paste, i.e. compound preparation water extract.
Mixing dried flowers of inula flower, dried fruits of broom cypress fruit, overground parts and seeds of agriophyllum squarrosum according to a mass ratio of 2:3:5, crushing uniformly, performing primary reflux for 4 hours by using a 95% ethanol solution with the mass volume fraction of 15 times, performing secondary reflux for 4 hours by using a 95% ethanol solution with the mass volume fraction of 12 times, performing tertiary reflux for 4 hours by using a 95% ethanol solution with the mass volume fraction of 10 times, concentrating an extracting solution under reduced pressure, suspending the extracting solution in water, and sequentially extracting by using petroleum ether and dichloromethane to respectively obtain a petroleum ether extract, a dichloromethane extract and an ethanol extract, namely a compound preparation petroleum ether extract, a compound preparation dichloromethane extract and a compound preparation ethanol extract.
EXAMPLE 3 anti-influenza Virus of drugs
Preparation of extracts of flowers and aerial parts of Inula japonica
(1) Aqueous extracts
Taking 50g of dried inula flower, adding 12 times of water by mass, decocting for 30 minutes, filtering with 4 layers of gauze, adding 8 times of water to residues, decocting for 15 minutes, and combining filtrates to form a paste. The mixture was formed into a paste on a water bath, which was first poured into a large evaporation dish and then into a small evaporation dish to form a paste, and 9.3g of inula flower water extract was obtained.
Taking 50g of dried inula flower overground part (flower removed), adding 15 times of water by mass, decocting for 40 minutes, filtering by 4 layers of gauze, adding 10 times of water to residues, decocting for 20 minutes, and combining filtrates to form a paste to obtain 8.7g of inula flower overground part water extract.
(2) Ethanol extract
Taking 50g of dried inula flower, adding 14 times of 95 v/v% ethanol solution by mass, decocting for 20 minutes, filtering with 4 layers of gauze, adding 6 times of 95 v/v% ethanol solution by mass to residues, decocting for 15 minutes, and combining filtrates to form a paste to obtain 2.6g of inula flower alcohol extract.
Taking 50g of the overground part of the dried inula flower (flower is removed), adding 12 times of 95 v/v% ethanol solution by mass, decocting for 30 minutes, filtering by 4 layers of gauze, adding 10 times of 95 v/v% ethanol solution by mass to the residue, decocting for 15 minutes, and combining the filtrates to form a paste to obtain 1.5g of the overground part ethanol extract of the inula flower.
Inhibition of cytopathic effects
At 3 × 104One/well inoculated MDCK cells in 96-well cell plates (100. mu.L per well), 5% CO at 37 ℃2Incubating for 24h, and performing subsequent tests when the cell density reaches 80%;
1) removing cell culture supernatant, adding 50 μ L gradient concentration drug virus culture medium to treat cells, and using the inula flower water extract, inula flower alcohol extract, inula flower above-ground water extract, inula flower above-ground alcohol extract, fructus kochiae water extract, fructus kochiae alcohol extract, fructus kochiae above-ground water extract, fructus kochiae above-ground alcohol extract, compound preparation water extract, compound preparation alcohol extract, compound preparation dichloromethane extract and compound preparation petroleum ether extract of examples 1, 2 and 3 to make their final concentrations respectively as in tables 1-14 below.
2) At the same time, 50. mu.L of influenza virus infection was added to the drug group. Influenza viruses of H1N1 type (a/17/California/2009/38 strain, hereinafter abbreviated to H1N1(California)) (MOI ═ 0.005), influenza viruses of H1N1 type (a/New-York/61/2015-CDC-LV16A strain, hereinafter abbreviated to H1N1(New-York)) (MOI ═ 0.005), influenza viruses of H3N2 type (a/17/HongKong/2014/8296 strain, hereinafter abbreviated to H3N2 (HongKong)) (MOI ═ 0.04) were used as the virus culture medium, respectively; setting cell control group without virus and virus control group without drug, setting 3 multiple wells for each concentration, placing into a container containing 5% CO at 35 deg.C2The incubator is infected for 1h, and the cell plate is shaken once every half an hour;
3) after 1h, each well is washed once by using 100 mu L of sterile PBS buffer solution, and then virus culture medium with the corresponding final concentration of the medicine is added;
4) at 48h post administration, CellTiter-
Figure BDA0002628379990000081
Transferring the detection reagent of 100 mu L into a porous plate after 5min, and detecting a fluorescence signal under 560nm excitation light by using a multi-labeled porous plate;
5) from the fluorescence signal, the inhibition ratio of cytopathic effect at each drug concentration was calculated as [ (fluorescence value of infection-administered group-fluorescence value of infection control group)/fluorescence value of cell control group ] × 100%.
The anti-influenza test results are shown in tables 1-8: the inula flower water extract, the inula flower alcohol extract, the inula flower overground part water extract and the inula flower overground part alcohol extract have strong inhibition effects on cytopathic effects caused by the influenza A H1N1(California) and H1N1(New-York) infection, but have weak inhibition effects on the cytopathic effects caused by the influenza A H3N2(Hongkong) infection. Similarly, the aqueous extract, the alcoholic extract, the aqueous extract and the alcoholic extract of the aerial parts of the broom cypress have strong inhibition effects on the cytopathic effect caused by the infection of the H1N1(California) and H1N1(New-York) influenza viruses, but have weak inhibition effects on the cytopathic effect caused by the infection of the H3N 2A (Hongkong) influenza viruses.
TABLE 1 inhibition of cytopathic effects of Inula japonica water extract on H1N1(California), H1N1(New-York), H3N2(Hongkong) influenza virus infection
Figure BDA0002628379990000091
TABLE 2 alcohol extract of Inula japonica inhibiting the cytopathic effects of H1N1(California), H1N1(New-York), H3N2(Hongkong) influenza virus infection
Figure BDA0002628379990000092
TABLE 3 inhibitory Effect of water extracts of aerial parts of Inula japonica on the cytopathic effects of H1N1(California), H1N1(New-York), H3N2(Hongkong) influenza virus infection
Figure BDA0002628379990000101
TABLE 4 inhibitory Effect of alcohol extracts of aerial parts of Inula japonica on the cytopathic Effect of H1N1(California), H1N1(New-York), H3N2(Hongkong) influenza Virus infection
Figure BDA0002628379990000102
Figure BDA0002628379990000111
TABLE 5 inhibition of the cytopathic effect of H1N1(California), H1N1(New-York), H3N2(HongKong) influenza virus infection by aqueous extracts of Kochia scoparia
Figure BDA0002628379990000112
TABLE 6 inhibition of cytopathic effects of H1N1(California), H1N1(New-York), H3N2(HongKong) influenza virus infection by alcohol extracts of Kochia scoparia
Figure BDA0002628379990000113
Figure BDA0002628379990000121
TABLE 7 inhibitory Effect of the water extract of aerial parts of Kochia scoparia on the cytopathic effect caused by H1N1(California), H1N1(New-York), H3N2(Hongkong) influenza virus infection
Figure BDA0002628379990000122
TABLE 8 inhibitory Effect of the alcohol extract of aerial parts of Kochia scoparia on the cytopathic Effect of H1N1(California), H1N1(New-York), H3N2(Hongkong) influenza Virus infection
Figure BDA0002628379990000123
Figure BDA0002628379990000131
The anti-influenza test results are shown in tables 9-14: the compound preparation water extract and compound preparation alcohol extract have excellent anti-H1N 1(California), anti-H1N 1(Nork York) and anti-H3N 2(Hong Kong) effects; the dichloromethane extract and petroleum ether extract of the compound preparation have weak resistance to H1N1(California), H1N1(Nork York) and H3N2(Hong Kong).
TABLE 9 inhibitory Effect of Compound preparation Water extract on cytopathic Effect caused by H1N1(California) influenza Virus infection
Figure BDA0002628379990000132
TABLE 10 inhibitory Effect of Compound preparation Water extract on cytopathic Effect caused by H1N1(New-York) influenza Virus infection
Figure BDA0002628379990000133
Figure BDA0002628379990000141
TABLE 11 inhibition of cytopathic effects of aqueous extracts of the Compound preparation against H3N2(HongKong) influenza Virus infection
Figure BDA0002628379990000142
TABLE 12 inhibitory Effect of alcoholic extracts of the Compound preparation on the cytopathic Effect of H1N1(California) influenza Virus infection
Figure BDA0002628379990000143
Figure BDA0002628379990000151
TABLE 13 inhibitory Effect of alcohol extracts of Compound preparations on cytopathic Effect caused by H1N1(New-York) influenza Virus infection
Figure BDA0002628379990000152
TABLE 14 inhibitory Effect of alcoholic extracts of Complex preparations on cytopathic Effect caused by H3N2(HongKong) influenza Virus infection
Figure BDA0002628379990000153
Figure BDA0002628379990000161
Example 4 drug inhibition of influenza virus nucleic acid replication
1) At 2 × 105One/well inoculated MDCK cells in 24-well cell platesMedium (500. mu.L of culture medium per well), 5% CO at 37 ℃2Incubating for 24h, and performing subsequent tests when the cell density reaches 80%;
2) the supernatant was aspirated off, and 250 μ L of virus medium containing the drug was added to give final drug concentrations: water extract of Inula flower: 200 mu g/mL; water extract of aerial parts of inula flower: 100 mu g/mL; ethanol extract of aerial parts of inula flower: 100 mu g/mL; water extract of aerial parts of broom cypress fruit: 50 mu g/mL; alcohol extract of aerial part of broom cypress fruit: 200 mu g/mL; water extract of compound preparation: 100 mu g/mL; alcohol extract of compound preparation: 100 mu g/mL;
3) meanwhile, a virus culture medium containing 250 μ L H1N1(California) (MOI ═ 0.005), H1N1(New-York) (MOI ═ 0.005), H3N2(HongKong) (MOI ═ 0.04) was added to the administration group; setting control group without virus infection and virus contrast without drug treatment, setting 3 parallel controls for different drugs, placing into a container at 35 deg.C containing 5% CO2The incubator is infected for 1h, and the cell plate is shaken once every half an hour;
4) after 1h, each well was washed once with 100. mu.L of sterile PBS buffer, and 500. mu.L of the culture medium containing the drug (final concentration as above) was added; after 12h, discarding the supernatant and collecting cells;
5) viral RNA was extracted using an RNA extraction kit for virus detection (tiangen) according to the instructions;
6) one Step was used as per the instructions
Figure BDA0002628379990000162
PrimeScriptTMRT-PCR Kit II (TaKaRa) and influenza virus NP segment specific primers quantitatively detect the content of enterovirus 71 type RNA in cells, and the content is relatively quantified with a virus control group.
The results of the nucleic acid experiments are shown in tables 15-17: the extracts of Inula japonica, and Inula japonica are resistant to H1N1(California) and less resistant to H1N1(Nork York) and H3N2(Hong Kong). The compound preparation water extract and compound preparation alcohol extract have strong resistance to H1N1(California), H1N1(Nork York) and H3N2(Hong Kong).
TABLE 15 inhibitory Effect of Individual herb extracts on viral genomic RNA replication in H1N1(California) influenza Virus-infected cells
Figure BDA0002628379990000171
TABLE 16 inhibition of viral genome RNA replication in H1N1(California), H1N1(New-York), H3N2(Hongkong) influenza virus infected cells by water extract of the combination preparation
Figure BDA0002628379990000172
Figure BDA0002628379990000181
TABLE 17 inhibitory Effect of alcoholic extracts of the Complex formulation on viral genomic RNA replication in H1N1(California), H1N1(New-York), H3N2(Hongkong) influenza virus-infected cells
Figure BDA0002628379990000182
Comparative example 1
The inventor replaces the samphire of the compound preparation in the example 2 with gardenia to perform anti-influenza virus test, and finds that the anti-influenza virus test has weaker resistance to H3N2 and has obvious effect difference with the anti-H3N 2 effect of the water extract or alcohol extract of the compound preparation in the example 2.
The inventor also carries out other replacement tests with similar drug properties, and the anti-H3N 2 effect is weak.
Comparative example 2
Based on the compound preparation in the example 2, a certain amount of the radix linderae, the astragalus mongholicus, the sea buckthorn and the trollius chinensis are added, the same medicine concentration is found, the effect difference of the compound preparation water extract or alcohol extract with the anti-H1N 1 and anti-H3N 2 is obvious, and the anti-H1N 1 and anti-H3N 2 are weaker.
Comparative example 3
The dried inula flower, the dried fruit of fructus kochiae, the overground part of the agriophyllum squarrosum and the seeds in the example 2 are mixed according to the mass ratio of 4:2:4 or 1:1:1 to prepare the compound preparation, and the compound preparation is subjected to an anti-influenza virus test, so that the anti-H1N 1 and the anti-H3N 2 of the compound preparation are weak, and the effect is obviously different from that of the water extract or the alcohol extract of the compound preparation in the example 2 in the anti-H1N 1 and the anti-H3N 2.
The above embodiments are preferred embodiments of the present disclosure, but the embodiments of the present disclosure are not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present disclosure should be regarded as equivalent replacements within the scope of the present disclosure.

Claims (10)

1. Application of Kochiae fructus and/or Kochiae fructus water extract and/or Kochiae fructus alcohol extract in preparing anti-influenza virus pharmaceutical composition or pharmaceutical preparation is provided.
2. Application of Kochia scoparia and/or a Kochia scoparia water extract and/or a Kochia scoparia alcohol extract in preparing a pharmaceutical composition or a pharmaceutical preparation capable of inhibiting cytopathic effect caused by influenza virus infection and viral genome RNA replication in influenza virus infected cells.
3. The use according to claim 1 or 2, wherein the influenza virus is influenza a virus and/or influenza b virus, and further wherein the influenza virus is H1N1 influenza a virus and/or H3N2 influenza a virus.
4. The use as claimed in claim 1 or claim 2, wherein the alcohol extract of Kochiae fructus is an ethanol extract of Kochiae fructus;
further, the fructus kochiae ethanol extract is prepared by the following method:
decocting aerial parts of Kochiae fructus with ethanol solution, and filtering; decocting the residue with ethanol solution, and mixing filtrates to obtain Kochiae fructus ethanol extract;
furthermore, the volume fraction of the ethanol solution is 90-95%.
5. A pharmaceutical composition for resisting influenza viruses is characterized by comprising belvedere fruit or an active ingredient of the belvedere fruit.
6. The pharmaceutical composition of claim 5, wherein the effective component of Kochia scoparia is prepared by aqueous or alcoholic extraction.
7. The anti-influenza virus pharmaceutical composition is characterized by being prepared from the following raw materials in parts by weight:
45-55 parts of sargentgloryvine root, 25-35 parts of inula flower and 15-25 parts of fructus kochiae.
8. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition is prepared from the following raw materials in parts by weight:
50 parts of sargentgloryvine root, 30 parts of inula flower and 20 parts of fructus kochiae;
furthermore, the overground part and seeds of the agriophyllum squarrosum, the flowers of the inula flower and the fruits of the broom cypress fruit are adopted as the medicine.
9. A process for the preparation of a pharmaceutical composition according to claim 7 or 8, characterized in that it comprises the following steps:
mixing the raw materials in a certain weight ratio, and extracting with ethanol solution or water for several times to obtain extractive solution, i.e. the pharmaceutical composition.
10. A pharmaceutical preparation against influenza virus, which is prepared from the pharmaceutical composition of any one of claims 5 to 8 and pharmaceutically acceptable excipients.
CN202010803851.5A 2020-08-11 2020-08-11 Mongolian medicine for resisting influenza virus, pharmaceutical composition, preparation method and application thereof Active CN111773258B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010803851.5A CN111773258B (en) 2020-08-11 2020-08-11 Mongolian medicine for resisting influenza virus, pharmaceutical composition, preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010803851.5A CN111773258B (en) 2020-08-11 2020-08-11 Mongolian medicine for resisting influenza virus, pharmaceutical composition, preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN111773258A true CN111773258A (en) 2020-10-16
CN111773258B CN111773258B (en) 2022-07-22

Family

ID=72762723

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010803851.5A Active CN111773258B (en) 2020-08-11 2020-08-11 Mongolian medicine for resisting influenza virus, pharmaceutical composition, preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN111773258B (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241310A (en) * 2001-02-21 2002-08-28 Taisho Pharmaceut Co Ltd Locally applying composition
WO2005067948A2 (en) * 2004-01-13 2005-07-28 Jinhua Wang Biological medicine for treating various diseases caused by various virus, bacterial infection
JP2013112644A (en) * 2011-11-29 2013-06-10 Obihiro Univ Of Agriculture & Veterinary Medicine Anti-influenza virus agent and production method of the same
CN103599148A (en) * 2013-11-15 2014-02-26 沈阳药科大学 Agriophyllum squarrosum total flavonoid extract, and preparation method and application thereof
CN108030796A (en) * 2017-12-18 2018-05-15 王秀兰 A kind of anaesthetic of resisiting influenza virus and preparation method thereof
KR20190096745A (en) * 2018-02-09 2019-08-20 전남대학교산학협력단 Compositions for Anti-Influenza Virus comprising Lichen Extract

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241310A (en) * 2001-02-21 2002-08-28 Taisho Pharmaceut Co Ltd Locally applying composition
WO2005067948A2 (en) * 2004-01-13 2005-07-28 Jinhua Wang Biological medicine for treating various diseases caused by various virus, bacterial infection
JP2013112644A (en) * 2011-11-29 2013-06-10 Obihiro Univ Of Agriculture & Veterinary Medicine Anti-influenza virus agent and production method of the same
CN103599148A (en) * 2013-11-15 2014-02-26 沈阳药科大学 Agriophyllum squarrosum total flavonoid extract, and preparation method and application thereof
CN108030796A (en) * 2017-12-18 2018-05-15 王秀兰 A kind of anaesthetic of resisiting influenza virus and preparation method thereof
KR20190096745A (en) * 2018-02-09 2019-08-20 전남대학교산학협력단 Compositions for Anti-Influenza Virus comprising Lichen Extract

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
刘建萍等: "地肤子皂苷抗变态反应作用及其量效关系的研究", 《江苏农业科学》 *
朱亚民等: "《内蒙古植物药志 第1卷》", 31 December 2000, 内蒙古人民出版社 *
王北婴等: "《中药新药研制开发技术与方法》", 31 December 2001, 上海科学技术出版社 *
王晓曼等: "肥大细胞在抗感染免疫作用中的研究进展", 《医学研究与教育》 *
田莉: "中药中神经氨酸酶抑制剂的筛选及其抗流感病毒实验研究", 《中国博士学位论文全文数据库医药卫生科技辑》 *

Also Published As

Publication number Publication date
CN111773258B (en) 2022-07-22

Similar Documents

Publication Publication Date Title
WO2018210228A1 (en) Antiviral traditional chinese medicine composition, preparation method therefor and application thereof
CN113616747B (en) Traditional Chinese medicine composition for healing infectious diseases and application thereof
KR20040012447A (en) Herbal pharmaceutical composition for treatment of hiv/aids patients
JP6605036B2 (en) Method for preparing a medicinal composition for preventing or treating liver and kidney damage-related diseases
CN101773527B (en) Pinecone extractive of Yunnan Pinus and preparation method and medicinal application thereof
KR20220156605A (en) Application of Traditional Chinese Medicine Compositions in Preparation of Drugs for Treatment or Prevention of Coronavirus Infection
CN102114113A (en) Preparation method of Chinese pulsatilla root decoction granules
CN101099787A (en) Traditional Chinese medicinal composition with remarkable wide-spectrum antiviral action
CN111773258B (en) Mongolian medicine for resisting influenza virus, pharmaceutical composition, preparation method and application thereof
CN102813713B (en) Rhizoma dryopteris crassirhizomae and fructus crataegi composition, preparation method and application of composition
CN103251908B (en) Hair-restorer and preparation method thereof
CN105617021A (en) Medicine or health product taking dendrobium officinale and beautiful millettia root as raw materials
TW200427456A (en) An herbal extract having anti-virus activity and preparation of same
CN102120000B (en) Composition of effective parts of traditional Chinese medicine preparation for resisting Coxsackie virus B and preparation method thereof
CN104815007A (en) Medicinal composition for preventing and treating infectious bronchitis of chicken as well as preparation method and application thereof
CN104857393A (en) Pharmaceutical preparation for treating arrhythmia
CN107753551B (en) Composition with function of reducing blood pressure and preparation method thereof
CN104208168B (en) A kind of for compound traditional Chinese medicine composite treating poultry respiratory infection and preparation method thereof
CN108743654B (en) Traditional Chinese medicine composition for treating ischemic heart disease and preparation method and application thereof
CN113101331B (en) Thyme herb tea and preparation method and application thereof
CN101982187B (en) Walnut shell extract and anti-HIV pharmaceutical application thereof
CN103169856B (en) A kind of Chinese medicine composition containing Rhizoma Coptidis
CN105770188B (en) liver-protecting traditional Chinese medicine preparation and preparation method thereof
CN105998353A (en) Potato with liver benefiting effect and application thereof
CN106038757A (en) Traditional Chinese medicine preparation for treating hypertension and preparation and application of traditional Chinese medicine preparation for treating hypertension

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant